4//SEC Filing
Voliotis Dimitris 4
Accession 0001725160-21-000037
CIK 0001725160other
Filed
Feb 15, 7:00 PM ET
Accepted
Feb 16, 7:01 PM ET
Size
7.2 KB
Accession
0001725160-21-000037
Insider Transaction Report
Form 4
Voliotis Dimitris
SVP, Clinical Development
Transactions
- Award
Common Stock
2021-02-11+6,250→ 6,250 total - Award
Stock Option (Right to Buy)
2021-02-11+18,750→ 18,750 totalExercise: $38.76Exp: 2031-02-10→ Common Stock (18,750 underlying)
Footnotes (2)
- [F1]Represents restricted stock units, each of which represent a contingent right to receive one share of common stock, and which will vest in substantially equal annual installments over a four year period following the grant date.
- [F2]The option vests and becomes exercisable in 48 substantially equal monthly installments following the grant date.
Documents
Issuer
Zentalis Pharmaceuticals, Inc.
CIK 0001725160
Entity typeother
Related Parties
1- filerCIK 0001807910
Filing Metadata
- Form type
- 4
- Filed
- Feb 15, 7:00 PM ET
- Accepted
- Feb 16, 7:01 PM ET
- Size
- 7.2 KB